Abselion, a life sciences technology company focused on simplifying biomolecule quantification, has appointed Dale Gordon as chair of the board of directors.

The firm, which recently established a US subsidiary, says it is committed to building a well-governed organisation that can support collaboration and reliable delivery as interest in its Amperia protein quantification system grows internationally.

Gordon’s background spans bioprocessing, company building and board leadership. Most recently, he served as CEO of Mirus Bio, a leading provider of transfection technologies widely used in viral vector production, where he led the business through a period of significant growth and strategic development. He was also CEO at Gemini Bio and held leadership roles at GE Life Sciences (now Cytiva), and Merck Millipore.

He succeeds Simon Douglas, who is stepping down from the role after serving as chair of the board for over four years.